Beskrivelse
Krav
Fullmektig i Norge:
Fullmektig i EP:
2012.11.02, AU 2012904828
2012.11.05, AU 2012904868
CN-A- 1 939 290 (B1)
WO-A2-92/15282 (B1)
E W Chia ET AL: "Colchicine suppresses neutrophil superoxide production in a murine model of gouty arthritis: a rationale for use of low-dose colchicine : Colchicine inhibits superoxide production in gout", BRITISH JOURNAL OF PHARMACOLOGY, vol. 153, no. 6, 1 March 2008 (2008-03-01) , pages 1288-1295, XP055572571, UK ISSN: 0007-1188, DOI: 10.1038/bjp.2008.20 (B1)
GABRIELYAN ET AL: "516 Comparative effects of losartan and losartan colchicines combination therapy in unstable angina patients with hyperuricaemia", EUROPEAN JOURNAL OF ECHOCARDIOGRAPHY, HARCOURT PUBLISHERS, EDINBURGH, GB, vol. 7, 1 December 2006 (2006-12-01), page S83, XP005807173, ISSN: 1525-2167, DOI: 10.1016/S1525-2167(06)60306-5 (B1)
LAGRUE G ET AL: "Effect of colchicine on atherosclerosis. I. Clinical and biological studies", CLINICAL PHYSIOLOGY AND BIOCHEMISTRY, BASEL, CH, vol. 3, no. 5, 1 January 1985 (1985-01-01) , pages 221-225, XP009190020, ISSN: 0252-1164 (B1)
N. SCHLESINGER ET AL: "Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study", ANNALS OF THE RHEUMATIC DISEASES, vol. 70, no. 7, 1 July 2011 (2011-07-01), pages 1264-1271, XP055272366, GB ISSN: 0003-4967, DOI: 10.1136/ard.2010.144063 (B1)
N. Schlesinger ET AL: "Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study", Annals of the Rheumatic Diseases, vol. 70, no. 7, 1 July 2011 (2011-07-01), pages 1264-1271, XP055572564, GB ISSN: 0003-4967, DOI: 10.1136/ard.2010.144063 (B1)
NAKAMURA Y ET AL: "Role of microtubules in ischemic preconditioning against myocardial infarction", CARDIOVASCULAR RESEARCH, OXFORD UNIVERSITY PRESS, GB, vol. 64, no. 2, 1 November 2004 (2004-11-01), pages 322-330, XP004600509, ISSN: 0008-6363, DOI: 10.1016/J.CARDIORES.2004.07.013 (B1)
NINA C RAJU ET AL: "Effect of colchicine compared with placebo on high sensitivity C-reactive protein in patients with acute coronary syndrome or acute stroke: a pilot randomized controlled trial", JOURNAL OF THROMBOSIS AND THROMBOLYSIS, KLUWER ACADEMIC PUBLISHERS, BO, vol. 33, no. 1, 15 September 2011 (2011-09-15), pages 88-94, XP035001736, ISSN: 1573-742X, DOI: 10.1007/S11239-011-0637-Y (B1)
O'KEEFE J H JR ET AL: "INEFFECTIVENESS OF COLCHICINE FOR THE PREVENTION OF RESTENOSIS AFTER CORONARY ANGIOPLASTY", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, ELSEVIER, NEW YORK, NY, US, vol. 19, no. 7, 1 January 1992 (1992-01-01), pages 1597-1600, XP008069957, ISSN: 0735-1097 (B1)
STEFAN M. NIDORF ET AL: "Low-Dose Colchicine for Secondary Prevention of Cardiovascular Disease", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 61, no. 4, 1 January 2013 (2013-01-01), pages 404-410, XP055147314, ISSN: 0735-1097, DOI: 10.1016/j.jacc.2012.10.027 (B1)
US-A1- 2006 286 108 (B1)
US-A1- 2011 190 397 (B1)
WO-A1-2010/046628 (B1)
WO-A2-2007/048004 (B1)
WO-A2-2008/131192 (B1)
DINA M SPARANO ET AL: "Pericarditis and Pericardial Effusion: Management Update", CURRENT TREATMENT OPTIONS IN CARDIOVASCULAR MEDICINE, CURRENT SCIENCE INC, NEW YORK, vol. 13, no. 6, 12 October 2011 (2011-10-12), pages 543-555, XP019972043, ISSN: 1534-3189, DOI: 10.1007/S11936-011-0151-8 (B1)
Statushistorie
Hovedstatus | Beslutningsdato, detaljstatus |
---|---|
EP patent gjort gjeldende i Norge | EP patent besluttet gjeldende i Norge |
EP under behandling | Forespørsel om å gjøre EP patent gyldig er mottatt |
Korrespondanse
Dato
Type korrespondanse
Journal beskrivelse
|
---|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Utgående
EP Varsel om betaling av første årsavgift (3319) (PTEP2914255)
|
Utgående
EP Registreringsbrev (3210) (PTEP2914255)
|
Innkommende, AR451642553
Søknadsskjema Patent
|
Innkommende
EP Publiseringsdokument fra EPO
|
Til betaling:
Neste fornyelse/årsavgift:
Betalingshistorikk:
Beskrivelse / Fakturanummer | Betalingsdato | Beløp | Betaler | Status |
---|---|---|---|---|
Årsavgift 12. avg. år (EP) | 2024.11.25 | 5010 | 1/DENNEMEYER CO S.A R.L. | Betalt og godkjent |
Årsavgift 11. avg. år (EP) | 2023.11.24 | 3500 | 1/DENNEMEYER CO S.A R.L. | Betalt og godkjent |
Årsavgift 10. avg. år (EP) | 2022.11.08 | 3200 | CPA GLOBAL LIMITED | Betalt og godkjent |
Årsavgift 9. avg. år (EP) | 2021.11.19 | 2850 | PAVIS PAYMENTS GMBH | Betalt og godkjent |
32115732 expand_more expand_less | 2021.10.22 | 5580 | Budde Schou A/S | Betalt |
Gebyr ved bruk av MasterCard-kort
80 = 80 X 1
Valideringsgebyr EP-patent
5500 = 1 X 5500
|